Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITPR3 | Q14573 | 9/20 | 0.61 |
| ▸ | ITPR1 | Q14643 | 5/20 | 0.61 |
| ▸ | ITPR2 | Q14571 | 4/20 | 0.61 |
| ▸ | INPP5A | Q14642 | 2/20 | 0.61 |
| ▸ | INPPL1 | O15357 | 1/20 | 0.56 |
| ▸ | AKT1 | P31749 | 1/20 | 0.56 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5417857 | 0.96 | ITPR3 (0.61) | ITPR3ITPR1ITPR2INPP5AINPPL1 | |
| SCHEMBL7117013 | 0.94 | ITPR3 (0.54) | ITPR3ITPR1ITPR2INPP5AINPPL1 | |
| SCHEMBL1356398 | 0.94 | ITPR3 (0.54) | ITPR3ITPR1ITPR2INPP5AINPPL1 | |
| SCHEMBL1322462 | 0.94 | ITPR3 (0.54) | ITPR3ITPR1ITPR2INPP5AINPPL1 | |
| SCHEMBL9165530 | 0.94 | ITPR3 (0.54) | ITPR3ITPR1ITPR2INPP5AINPPL1 | |
| SCHEMBL462454 | 0.94 | ITPR3 (0.54) | ITPR3ITPR1ITPR2INPP5AINPPL1 | |
| SCHEMBL11233751 | 0.94 | ITPR3 (0.60) | ITPR3ITPR1ITPR2INPP5AINPPL1 | |
| SCHEMBL7171543 | 0.94 | ITPR3 (0.60) | ITPR3ITPR1ITPR2INPP5AINPPL1 | |
| SCHEMBL639515 | 0.94 | ITPR3 (0.54) | ITPR3ITPR1ITPR2INPP5AINPPL1 | |
| SCHEMBL19712150 | 0.94 | ITPR3 (0.58) | ITPR3ITPR1ITPR2INPP5AINPPL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8906604-B2 | Store-operated calcium cellular assay | NATIONAL CENTER FOR BIOLOGICAL SCIENCES (IN) | 2014-12-09 | — | — | US | claimed |
| US-20130260409-A1 | STORE-OPERATED CALCIUM CELLULAR ASSAY | NATIONAL CENTER FOR BIOLOGICAL SCIENCES (IN) | 2013-10-03 | — | — | US | claimed |
| US-8476006-B2 | Store-operated calcium cellular assay | NATIONAL CENTER FOR BIOLOGICAL SCIENCES (IN) | 2013-07-02 | — | — | US | claimed |
| CN-114699417-B | Application of sodium inositol hexaphosphate in intestinal rehabilitation of children short bowel syndrome | 上海交通大学医学院附属新华医院 | 2024-01-09 | — | — | CN | disclosed |
| EP-4275705-A2 | PANCREATITIS TREATMENT | Calcimedica, Inc. (US) | 2023-11-15 | — | — | EP | disclosed |
| CN-112028875-B | Anhydride compounds of PGI2 protein agonist and TXA2 protein inhibitor | 南昌弘益科技有限公司 | 2023-08-15 | — | — | CN | disclosed |
| EP-3261641-B1 | PANCREATITIS TREATMENT | CALCIMEDICA INC (US) | 2023-07-12 | — | — | EP | disclosed |
| CN-115772335-A | Flame-retardant low-dielectric LCP-based LDS composite material and preparation method thereof | 宁夏清研高分子新材料有限公司 | 2023-03-10 | — | — | CN | disclosed |
| CN-111789956-B | Drug therapy, screening technology and kit for inhibiting side effects caused by chemotherapy | 耶鲁大学 | 2023-02-17 | — | — | CN | disclosed |
| US-11311535-B2 | Pancreatitis treatment | CALCIMEDICA, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| CN-108998432-B | Acid phosphatase gene and application | 中国农业科学院农业资源与农业区划研究所 | 2022-04-12 | — | — | CN | disclosed |
| US-6251622-B1 | TREATING OR PREVENTING LEUKOCYTE-MEDIATED INJURY OR INFLAMMATORY RESPONSE BY ADMINISTERING FARNESYL DIPOHSPHATE, PRESQUALENE DIPHOSPHATE, FARNESYL MONOPHOSPHATE, PRESQUALENE MONOPHOSPHATE OR PRESQUALENE DIPHOSPHATE ANALOG | BRIGHAM & WOMEN'S HOSPITAL | 2001-06-26 | — | — | US | disclosed |
| US-20010001062-A1 | Screening methods for presqualene diphosphate analogs | BRIGHAM & WOMEN'S HOSPITAL | 2001-05-10 | — | — | US | disclosed |
| US-6066466-A | Screening methods for presqualene diphosphate analogs | BRIGHAM & WOMENS HOSPITAL (US) | 2000-05-23 | — | — | US | disclosed |
| US-6008205-A | Polyisoprenyl phosphate stable analogs for regulation of neutrophil responses | THE BRIGHAM & WOMEN'S HOSPITAL, INC. (US) | 1999-12-28 | — | — | US | disclosed |
| US-5888829-A | Photolabile caged ionophores and method of using in a membrane separation process | MOLECULAR PROBES, INC. (US) | 1999-03-30 | — | — | US | disclosed |
| US-5872243-A | Caged nucleotides | MOLECULAR PROBES, INC. (US) | 1999-02-16 | — | — | US | disclosed |
| WO-1998045466-A1 | COMPOSITIONS AND SCREENING METHODS FOR NEUTROPHIL RESPONSES | BRIGHAM AND WOMEN'S HOSPITAL (US) | 1998-10-15 | — | — | WO | disclosed |
| WO-1997039122-A9 | ISOLATED AND CLONED MAST CELL 78 kDa PHOSPHOPROTEIN (MAST CELL DEGRANULATION INHIBITORY AGENT) AND USE THEREOF | — | 1998-03-26 | — | — | WO | disclosed |
| US-5336503-A | Administering a myosin light chaing kinase inhibitor | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1994-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11311535-B2 | Pancreatitis treatment | IAPP, PNLIP, VIP | ITPR3 47/4885ITPR1 50/4885ITPR2 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.